Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pioglitazone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 14/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.98 |
| ▸ | RXRA | P19793 | 1/20 | 0.98 |
| ▸ | MPC2 | O95563 | 1/20 | 0.67 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.67 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.54 |
| ▸ | PPARA | Q07869 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pioglitazone SCHEMBL29364546 | 1.00 | PPARG (1.00) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL29593116 | 1.00 | PPARG (1.00) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL1162440 | 1.00 | PPARG (1.00) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL503083 | 1.00 | PPARG (1.00) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL21844 | 1.00 | PPARG (1.00) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL23534417 | 0.99 | PPARG (0.98) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL2332117 | 0.99 | PPARG (0.98) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL1162192 | 0.99 | PPARG (1.00) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL3689044 | 0.99 | PPARG (1.00) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL21843 | 0.99 | PPARG (1.00) | PPARGCYP3A4RXRAMPC2CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 63501 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107250-A1 | METHODS AND SYSTEMS FOR PROFILING FATTY LIVER DISEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-21 | — | — | WO | claimed |
| US-12624116-B2 | Methods of treating severe insulin resistance by interfering with glucagon receptor signaling | REGENERON PHARMACEUTICALS, INC. (US) | 2026-05-12 | — | — | US | claimed |
| CN-122010656-A | Application of oxyalkylisourea in introducing methyl and isotopically-labeled methyl | 陕西师范大学 | 2026-05-12 | — | — | CN | claimed |
| US-20260124282-A1 | DECORIN FOR ITS USE IN THE TREATMENT OF DIABETES | CENTRE EUROPEEN D'ETUDE DU DIABETE (FR) | 2026-05-07 | — | — | US | claimed |
| US-20260126444-A1 | Biomarkers for Long COVID | UNIV SZEGEDI (HU) | 2026-05-07 | — | — | US | claimed |
| EP-4734978-A2 | COMBINATION THERAPIES USING PSILOCYBIN | University of Padova (IT) | 2026-05-06 | — | — | EP | claimed |
| WO-2026087695-A1 | TREATMENT FOR METABOLIC DISORDER | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| WO-2026087680-A1 | TREATMENT FOR CARDIOVASCULAR DISEASE | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| US-20260108482-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS INC (US) | 2026-04-23 | — | — | US | claimed |
| EP-4729635-A2 | DIAGNOSIS AND TREATMENT OF NAFLD AND LIVER FIBROSIS | Beth Israel Deaconess Medical Center, Inc. (US) | 2026-04-22 | — | — | EP | claimed |
| US-5457109-A | Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus | WARNER-LAMBERT COMPANY (US) | 1995-10-10 | — | — | US | claimed |
| WO-1995007697-A2 | USE OF THIAZOLIDINEDIONE DERIVATIVES AND RELATED ANTIHYPERGLYCEMIC AGENTS IN THE TREATMENT OF DISEASE STATES AT RISK FOR PROGRESSING TO NONINSULIN-DEPENDENT DIABETES MELLITUS | WARNER-LAMBERT COMPANY (US) | 1995-03-23 | — | — | WO | claimed |
| WO-1995007694-A1 | USE OF THIAZOLIDINEDIONES TO PREVENT OR DELAY ONSET OF NIDDM | SANKYO COMPANY, LIMITED (JP) | 1995-03-23 | — | — | WO | claimed |
| EP-0601001-A1 | PHARMACEUTICAL COMPOSITION CONTAINING 3-GUANIDINOPROPIONIC ACID AND PIOGLITAZONE GLIBENCLAMIDE OR GLIMEPIRIDE. | UPJOHN CO (US) | 1994-06-15 | — | — | EP | claimed |
| WO-1993003724-A1 | PHARMACEUTICAL COMPOSITION CONTAINING 3-GUANIDINOPROPIONIC ACID AND PIOGLITAZONE GLIBENCLAMIDE OR GLIMEPIRIDE | THE UPJOHN COMPANY (US) | 1993-03-04 | — | — | WO | claimed |
| US-5183823-A | PYRIDINE N-OXIDE COMPOUNDS WHICH ARE USEFUL AS HYPOGLYCEMIC AND HYPOLIPIDEMIC AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-02-02 | — | — | US | claimed |
| EP-0508740-A1 | Thiazolidinedione derivatives, their production and their use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-10-14 | — | — | EP | claimed |
| EP-0193256-B1 | THIAZOLIDINEDIONE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1989-04-05 | — | — | EP | claimed |
| US-4687777-A | pioglitazone and salts | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1987-08-18 | — | — | US | claimed |
| EP-0193256-A1 | Thiazolidinedione derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1986-09-03 | — | — | EP | claimed |